Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
When budgeting for a UK Responsible Person (UKRP) for 2026 and beyond, what are the key factors and service models that influence the overall cost? While specific fees vary between providers, understa...
For medical device manufacturers based outside the United Kingdom, appointing a UK Responsible Person (UKRP) is a critical step for market access. However, understanding the associated costs, particul...
When selecting an EU Authorised Representative (AR) under the Medical Device Regulation (EU) 2017/745 (MDR), what specific operational and strategic criteria should a non-EU manufacturer prioritize to...
When a non-EU cosmetic brand plans to enter the European market, designating an EU-based Responsible Person (RP) is a fundamental legal requirement. While the concept seems straightforward, the scope ...
For a non-EU-based manufacturer of a connected medical device, such as a Software as a Medical Device (SaMD) or a wearable biosensor that processes personal health data, navigating European market ent...
Given the significantly enhanced responsibilities and joint liability assigned to Authorized Representatives (AR) under the EU Medical Device Regulation (MDR), and in light of recent MDCG guidance cla...
When selecting an EU Authorized Representative (AR) under Regulation (EU) 2017/745 (MDR), what comprehensive due diligence process should a non-EU manufacturer implement beyond verifying the AR's phys...
As non-UK medical device manufacturers plan for the UK's evolving regulatory framework, what is a comprehensive methodology for selecting a UK Responsible Person (UKRP) that extends beyond the minimum...
For non-UK medical device manufacturers planning to enter or remain on the Great Britain market, appointing a UK Responsible Person (UKRP) is a mandatory step. While budgeting for this service is cruc...
When a non-EU cosmetics brand prepares for compliance with evolving EU regulations, what practical criteria should be used to evaluate and select a suitable Responsible Person (RP)? Beyond simply havi...
For non-EU medical device manufacturers, selecting an EU Authorised Representative (AR) under the MDR or IVDR is a critical compliance decision with significant legal implications. Beyond simply appoi...
When a manufacturer modifies a cleared Software as a Medical Device (SaMD) that incorporates a machine learning (ML) algorithm, how is the determination made whether the change requires a new 510(k) s...
For a medical device or Software as a Medical Device (SaMD) manufacturer that processes the personal health data of EU residents, how should the organization approach budgeting for a GDPR Article 27 r...
For non-EU medical device manufacturers, selecting an EU Authorized Representative (AR) is a critical compliance step under the EU Medical Device Regulation (MDR). This role extends far beyond a simpl...
Beyond the initial annual retainer fee, how can medical device manufacturers accurately forecast the total cost of partnership with an EU Authorized Representative (AR) under the stringent requirement...
With the FDA’s Quality Management System Regulation (QMSR) final rule taking effect on February 2, 2026, foreign medical device establishments must re-evaluate the capabilities of their U.S. Agent. Th...
When preparing to place a cosmetic product on the European Union market, manufacturers outside the EU must appoint a Responsible Person (RP). While specific fees vary, understanding the factors that d...
When evaluating the cost structure for an EU Responsible Person (RP) to ensure compliance with cosmetic regulations, what are the key service components and pricing models that a non-EU brand must ana...
When preparing a premarket submission for a connected medical device, such as a continuous glucose monitoring system or a software-based diagnostic tool, how should a sponsor approach cybersecurity do...
For non-EU based medical device and Software as a Medical Device (SaMD) manufacturers that process personal data of individuals in the European Union, what are the core functions and potential liabili...